COVID-19

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company…

1 year ago

Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO

VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0)…

1 year ago

Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a…

1 year ago

Senzo Secures an Additional $1.8M Investment for Its Novel Rapid Home-Test Diagnostic Platform

Senzo Health Limited (London, UK) ("Senzo"), a life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, this week announced an…

1 year ago

COSMOS HEALTH CEO Issues Letter to Shareholders

Company reaches major strategic inflection point, with operations and revenue ramp-up underway, to significantly accelerate in 2024 and beyondMaintains solid…

1 year ago

Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development

ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

1 year ago

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…

1 year ago

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit 

BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

1 year ago

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

 Fiscal Year 2024 First Quarter Highlights Net sales of $78.7 million as reported Includes $0.7 million of Dialysis and BioSentry…

1 year ago